Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal ...
Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.
Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s ...
Ocugen has synchronized pivotal clinical and regulatory milestones for its three retinal gene therapy programs into 2026 and early 2027, targeting retinitis pigmentosa, Stargardt disease, and ...
Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ...
Hosted on MSN
Ray secures $125m to advance retinal gene therapy
Ray Therapeutics has raised $125 million in Series B financing to progress late-stage development of its gene therapy pipeline for retinal diseases. Lead candidate RTX-015, now in Phase I for ...
RMAT designation enables intensified FDA engagement and potential accelerated pathways, implying preliminary clinical evidence for RTx-015 despite absent peer-reviewed efficacy details, endpoints, and ...
Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease gene therapy. The candidate improved the structure and function of the ...
The Breakthrough Prize Foundation awarded researchers involved in developing gene therapies for blindness and sickle cell ...
Three scientists have won the 2026 Breakthrough Prize for developing Luxturna — the world's first FDA-approved gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results